Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca receives Scottish recommendation for Nexium

AstraZeneca receives Scottish recommendation for Nexium

15th September 2010

AstraZeneca has received a positive recommendation for its gastro-oesophageal reflux disease (GORD) treatment Nexium to be used among paediatric patients in Scotland.

The Scottish Medicines Consortium has backed the orally-administered gastro-resistant treatment for use among children aged between one and 11 years old, a patient group for which the product was specifically designed.

It is estimated that around four in ten children in the UK are diagnosed with GORD, which is characterised by weight gain and the return of food from the stomach into the mouth.

According to AstraZeneca, Nexium's administration via granules for oral solution will make it easier for children to receive the treatment, particularly those who have trouble swallowing tablets.

Mark Jones, AstraZeneca's UK marketing company president, said: "This decision is good news for children who are affected by this condition and reflects AstraZeneca's commitment to this therapy area."

Earlier this week, AstraZeneca announced plans to ally with Cancer Research UK on the development of a potentially groundbreaking drug, which could prove effective against a range of cancers.ADNFCR-8000103-ID-800065358-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.